Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $1.14T rose 37859150.7% year over year, ahead of the +9732467.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 48103998.5% from the prior quarter. Over 3 fiscal years it compounded at -14.5% a year.
Context
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -19.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.14T+48103998.5% QoQ
- Last fiscal yearDec 2025
- $9.6M-19.3% YoY
- LTMMar 2026
- $1.14T+9732467.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.6M USD
- Year-over-year change
- -19.3%
- 4-year CAGR
- -4.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.6M | -19.3% |
| FY2024 | 2024-12-31 | 11.89M | -10.8% |
| FY2023 | 2023-12-31 | 13.34M | -13.3% |
| FY2022 | 2022-12-31 | 15.37M | +36.3% |
| FY2021 | 2021-12-31 | 11.28M | — |
Selling, General & Admin vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9732467.6% is the highest of 10, against a peer median of +14.2%.
- Over three fiscal years its annual growth of -14.5% compares with a peer median of +7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.14T USD | +9732467.6% | -14.5% | — | |
| LTM Mar 2026 | $99.54M USD | -33.2% | -27.7% | 46.3% | |
| LTM Mar 2026 | $37.43M USD | +18.7% | +65.2% | — | |
| LTM Mar 2026 | $23.59M USD | — | +2.2% | 2560.2% | |
| LTM Mar 2026 | $21.89M USD | -3.6% | +59.0% | — | |
| LTM Mar 2026 | $20.1M USD | +39.9% | +8.1% | — | |
| LTM Mar 2026 | $19.76M USD | -28.1% | -0.2% | 3951.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $17.4M USD | +18.2% | +41.6% | — |
GNLXGenelux Corporation | LTM Mar 2026 | $13.37M USD | +14.2% | +38.8% | 167162.5% |
| LTM Mar 2026 | CHF 11.38M CHF | +4.4% | +6.7% | 307.5% | |
| LTM Mar 2026 | $9.18M USD | +20.3% | -1.1% | 13.5% | |
| Peer median (excluding ALDX) | — | +14.2% | +7.4% | 1433.8% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.94M | 47.31M | 29.46M | 48.22M | 25.66M |
| Selling, General & Admin | 11.28M | 15.37M | 13.34M | 11.89M | 9.6M |
| Operating Expenses | 56.22M | 62.68M | 42.79M | 60.12M | 35.27M |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| EBITDA | (55.77M) | (60.07M) | (35.21M) | (53.68M) | (31.69M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (56.22M) | (62.68M) | (42.79M) | (60.12M) | (35.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 185.36K | 2.35M | 7.32M | 6.19M | 3.32M |
| Interest Expense | 1.74M | 1.69M | 2.07M | 1.93M | 1.91M |
| Other Income / Expenses | (1.56M) | 655.35K | 5.25M | 4.27M | 1.42M |
| Income Before Tax | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| EPS (Diluted) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| Weighted Avg Shares | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
| Weighted Avg Shares (Diluted) | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.